A 19-week Cognition Study of Levetiracetam in Children With Partial Onset Seizures

NCT ID: NCT00105040

Last Updated: 2015-03-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

87 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-09-30

Study Completion Date

2007-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A 12-week Evaluation Period will be used to characterize potential cognitive and neuropsychological effects of LEV (20 - 60 mg/kg/day), as adjunctive treatment in children 4 - 16 years old, inclusive, with refractory partial onset seizures when compared to adjunctive treatment with placebo.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Epilepsy, Partial

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Levetiracetam (LEV)

Oral tablets or oral solution at 20-60 mg/kg/d, divided into twice daily dosing.

Group Type EXPERIMENTAL

Levetiracetam

Intervention Type DRUG

Oral tablets or oral solution at 20-60 mg/kg/d, divided into twice daily dosing.

Matching Placebo (PBO)

Oral tablets and oral solution.

Group Type PLACEBO_COMPARATOR

Placebo (PB)

Intervention Type OTHER

Oral tablets and oral solution

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Levetiracetam

Oral tablets or oral solution at 20-60 mg/kg/d, divided into twice daily dosing.

Intervention Type DRUG

Placebo (PB)

Oral tablets and oral solution

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Keppra

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Pediatric subjects (4 - 16 years old) diagnosed with refractory partial onset seizures for a minimum of six months prior to Visit 1 experiencing at least two partial onset seizures during the four weeks prior to Visit 1 will be enrolled
* Subjects should be on a stable regimen of one or a maximum of two other antiepileptic drugs (AEDs) for at least 2 weeks prior to Visit 1
* Subject must have an Intelligence Quotient (IQ) as assessed during Visit 1 of at least 70
* Subject and parent/guardian should be fluent in English

Exclusion Criteria

* Subject must not have had previous treatment with levetiracetam unless, in the opinion of the investigator, the subject's previous treatment was inadequate in dose or duration to provide an accurate assessment of the therapy, or the effect of levetiracetam was confounded by concomitant medication
* Subject is receiving benzodiazepines on a routine or chronic basic and is unable to discontinue use four weeks prior to Visit 1
* Subject has seizures too close together to accurately count
* Subject has a current psychiatric disorder other than mild to moderate attention deficit, behavior, or learning disorders
Minimum Eligible Age

4 Years

Maximum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

UCB Pharma

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

UCB Clinical Trial Call Center

Role: STUDY_DIRECTOR

UCB Pharma

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Birmingham, Alabama, United States

Site Status

Phoenix, Arizona, United States

Site Status

Tucson, Arizona, United States

Site Status

Little Rock, Arkansas, United States

Site Status

La Jolla, California, United States

Site Status

Los Angeles, California, United States

Site Status

Denver, Colorado, United States

Site Status

Washington D.C., District of Columbia, United States

Site Status

Bradenton, Florida, United States

Site Status

Gainesville, Florida, United States

Site Status

Loxahatchee Groves, Florida, United States

Site Status

Miami, Florida, United States

Site Status

Orlando, Florida, United States

Site Status

Tallahassee, Florida, United States

Site Status

Tampa, Florida, United States

Site Status

Atlanta, Georgia, United States

Site Status

Augusta, Georgia, United States

Site Status

Chicago, Illinois, United States

Site Status

Voorhees Township, New Jersey, United States

Site Status

Buffalo, New York, United States

Site Status

New York, New York, United States

Site Status

Rochester, New York, United States

Site Status

Winston-Salem, North Carolina, United States

Site Status

Cleveland, Ohio, United States

Site Status

Hershey, Pennsylvania, United States

Site Status

Philadelphia, Pennsylvania, United States

Site Status

Pittsburgh, Pennsylvania, United States

Site Status

Charleston, South Carolina, United States

Site Status

Germantown, Tennessee, United States

Site Status

Dallas, Texas, United States

Site Status

Fort Worth, Texas, United States

Site Status

Galveston, Texas, United States

Site Status

Houston, Texas, United States

Site Status

Norfolk, Virginia, United States

Site Status

Richmond, Virginia, United States

Site Status

Seattle, Washington, United States

Site Status

Morgantown, West Virginia, United States

Site Status

Milwaukee, Wisconsin, United States

Site Status

Scarborough Village, Ontario, Canada

Site Status

Thornhill, Ontario, Canada

Site Status

Toronto, Ontario, Canada

Site Status

Bloemfontein, , South Africa

Site Status

Cape Town, , South Africa

Site Status

Capitol Park, , South Africa

Site Status

Johannesburg, , South Africa

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada South Africa

References

Explore related publications, articles, or registry entries linked to this study.

Levisohn PM, Mintz M, Hunter SJ, Yang H, Jones J; N01103 Levetiracetam Study Group. Neurocognitive effects of adjunctive levetiracetam in children with partial-onset seizures: a randomized, double-blind, placebo-controlled, noninferiority trial. Epilepsia. 2009 Nov;50(11):2377-89. doi: 10.1111/j.1528-1167.2009.02197.x. Epub 2009 Aug 21.

Reference Type RESULT
PMID: 19702752 (View on PubMed)

de la Loge C, Hunter SJ, Schiemann J, Yang H. Assessment of behavioral and emotional functioning using standardized instruments in children and adolescents with partial-onset seizures treated with adjunctive levetiracetam in a randomized, placebo-controlled trial. Epilepsy Behav. 2010 Jul;18(3):291-8. doi: 10.1016/j.yebeh.2010.04.017. Epub 2010 May 23.

Reference Type RESULT
PMID: 20547106 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2014-004396-23

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

N01103

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.